ライフサイエンスコーパス: HRT

1 HRT does not directly associate with either CRY2 or PHOT

2 HRT is a powerful predictor of both CD and arrhythmic ev

3 HRT measurement variability has recently been better cha

4 HRT measurements in right eyes differed slightly in rim

5 HRT overestimated optic disc area as compared to SD-OCT.

6 HRT power increases in combination with T-wave alternans

7 HRT rim area was larger than Cirrus measurements (P < 0.

8 HRT use (versus none) was associated with higher attachm

9 HRT use at entry or during the trial was not effective i

10 HRT use, subtypes, and duration of use; confounding vari

11 HRT users who develop receptor-positive early-stage dise

12 HRT VCDR and cup volume were significantly smaller than

13 HRT, GDx and OCT findings are assessed separately.

14 ion of the HRT operational software (HRT-3), HRT's ability to correctly classify glaucomatous optic n

15 women using (n = 238) or not using (n = 378) HRT were compared.

16 progestogen (HR = 0.78; 95% CI = 0.70-0.87) HRT.

17 progestogen (HR = 0.82; 95% CI = 0.76-0.88) HRT was associated with a reduced risk of asthma onset.

18 Abnormal HRT was a predictive marker for all the end points in he

19 The combination of abnormal HRT and T-wave alternans (5 cohorts: 1516 patients) incr

20 ch analyzed the predictive value of abnormal HRT for the defined end points.

21 ificantly different from normal discs in all HRT and OCT parameters (P<0.001).

22 d basophil histamine release test (Allerport HRT).

23 their randomized trials that estrogen alone HRT decreases the risk of breast cancer in postmenopausa

24 coding SNP (R73H) rs10490923 (P = 0.007) and HRT x ARMS2 intronic SNP rs17623531 (P = 0.019).

25 s the associations between dietary boron and HRT with lung cancer risk.

26 s pH of 6.5, temperature of 55 degrees C and HRT of 2 days, 2754 mg/L volatile fatty acids (VFAs) wer

27 indicating that temperature<60 degrees C and HRT>3 days are critical to operate these systems stably.

28 depth and HRT), dynamic control of depth and HRT was shown to increase productivity by 0.6-9.9% while

29 (constant and location-independent depth and HRT), dynamic control of depth and HRT was shown to incr

30 l thickness, pattern standard deviation, and HRT disc area, the following HRT parameters were associa

31 healthy controls with data on both diet and HRT.

32 ns between BC and both commission errors and HRT in boys, but BC was not significantly associated wit

33 rt study of the association between GORD and HRT found a statistically significant association betwee

34 ed among women reporting use of both HBC and HRT (OR = 2.59, 95% CI: 1.50, 4.46), long-term HRT use (

35 ke and the joint effects of boron intake and HRT on lung cancer risk in women.

36 isk or the joint effects of boron intake and HRT use on lung cancer risk.

37 al neurogenesis was elevated in both LRT and HRT rats that underwent endurance training on a treadmil

38 iation between a diagnosis of meningioma and HRT use, with an odds ratio of 2.2 (95% CI, 1.9 to 2.6;

39 classify glaucomatous optic neuropathy, and HRT's role in monitoring disease progression.

40 from Bland-Altman plots comparing SD-OCT and HRT measurements showed suboptimal agreement between the

41 odds ratio, FDT, oculokinetic perimetry, and HRT II are promising tests.

42 Dx-VCC versus StratusOCT for global RNFL and HRT-II versus StratusOCT for global ONH topography.

43 Based on the influence of sex and HRT on the prevalence of isolated IFG and isolated IGT,

44 which a balance between Notch signaling and HRT activity determines the expression of smooth muscle

45 Resistance to TCV and HRT gene expression in HRT act1 plants was inducible by

46 l or diffuse), or a combination thereof; and HRT-based Moorfields Regression Analysis (MRA) results o

47 GDx-VCC and HRT-II showed better repeatability than StratusOCT.

48 es between 55 degrees C and 65 degrees C and HRTs between 2 and 4 days on process performance, microb

49 OCT, and GDx VCC) and neuroretinal rim area (HRT II) and SAP sensitivity expressed in decibels were d

50 deviation (r = -0.44; P = 0.005) as well as HRT linear cup-to-disc ratio (r = 0.61; P < 0.001) and s

51 y Time Interaction in favor of DCS-augmented HRT (p < 0.01), controlling for baseline tic severity, t

52 ent of tic severity reductions by augmenting HRT with DCS compared with placebo augmentation.

53 Cell-based HRT (cHRT) is an alternative approach that may allow cer

54 here is a theoretical risk of estrogen-based HRT (e-HRT) leading to an increase in tumor growth and t

55 Each baseline HRT parameter was assessed in univariate and multivariat

56 Several baseline HRT parameters, alone or in combination with baseline cl

57 Furthermore, for women who first began HRT in the first 6 months of the trial compared with wom

58 trial compared with women who did not begin HRT, HRT seemed to be much more effective in controlling

59 The association between HRT and clinical periodontal measures was strongest amon

60 s study investigated the association between HRT and GORD in menopausal women using validated general

61 s evidence of a positive association between HRT use and diagnosis of meningioma, and therefore, HRT

62 g gaps in understanding the relation between HRT and breast cancer risk.

63 atusOCT measurements and are similar between HRT II and GDx VCC and these associations are generally

64 Exactly half as many eyes were abnormal by HRT MRA.

65 Optic nerve head parameters measured by HRT 3 were compared between fellow eyes.

66 n in optic nerve head parameters measured by HRT 3.

67 Using combination HRT (of any duration) was associated with a substantial

68 ween PPI use and oestrogen-only and combined HRT treatment.

69 mone use (oestrogen-only, tibolone, combined HRT and progestogen) were statistically significantly as

70 a measurements were larger than AL-corrected HRT and SD-OCT measurements (P < 0.001 for both) and the

71 The AL-corrected HRT disc area and uncorrected/corrected Cirrus disc area

72 Mean keratometry-corrected HRT disc area measurements were larger than AL-corrected

73 occoides mccartyi, were operated at a 50 day HRT and fed PCE (1.12 mM) and lactate (4.3 mM).

74 on lab-scale reactors performance at 20 days HRT, shifted from neutral to positive (energy gain aroun

75 e of 37% achieved at 55 degrees C and 4 days HRT.

76 Temporally defined HRT activity may constitute a negative feedback mechanis

77 emptying the anode for 1-3 days or different HRTs.

78 (HM/VTS) were targeted for treatment during HRT.

79 erences in the natural history of IM after e-HRT exposure.

80 a theoretical risk of estrogen-based HRT (e-HRT) leading to an increase in tumor growth and thus alt

81 Database for patients with >= 6 months of e-HRT.

82 These preliminary results suggest that e-HRT may be safe in incidental meningiomas.

83 Forty patients were included in the e-HRT group (mean age 62.1 +/- 12.0 years; mean duration o

84 age 2D tumor diameter was 35% lower in the e-HRT group (p = 0.02), with an absolute growth-rate of ha

85 were 1.2 years and 3.3 years longer in the e-HRT group, respectively.

86 Significance of change at each HRT superpixel between each follow-up and its nearest ba

87 When compared to the equivalent HRT measurements, SD-OCT-derived measures differed signi

88 To evaluate HRT effects, postmenopausal women using (n = 238) or not

89 deviation, and HRT disc area, the following HRT parameters were associated with the development of O

90 superonasal VF; logarithmic association) for HRT II; from 0.02 (temporal RNFL, nasal VF; linear assoc

91 ignificantly different from normal discs for HRT parameters, except for mean RNFL thickness and cup s

92 classification of outside normal limits for HRT and OCT or NFI >/= 56 (GDx).

93 icant inverse associations were observed for HRT (odds ratio [OR] = 0.65, 95% CI 0.48-0.90, P = 0.008

94 The strongest interactions were observed for HRT x ARMS2 coding SNP (R73H) rs10490923 (P = 0.007) and

95 nents of the widely prescribed drug used for HRT.

96 000 permuted topographic series derived from HRT images of 18 healthy eyes from Moorfields Eye Hospit

97 Rim area measurements from HRT were larger than from SD-OCT, likely a result of dif

98 In contrast, vertical C/D ratio from HRT-II, and horizontal C/D ratio from StratusOCT showed

99 and High Resolution GC x GC-TOF-MS (GC x GC HRT-4D).

100 (Di)-17 is conferred by the resistance gene HRT and a recessive locus rrt.

101 us (TCV) depends on the resistance (R) gene, HRT, and the recessive locus rrt.

102 arbors the sequence-related resistance genes HRT and RCY1 in different ecotypes.

103 When fed synthetic groundwater at 11-3.6 h HRT, the upflow bioreactor removed >99.7% of the influen

104 e(-) equiv L(-1) d(-1) was achieved at 3.6 h HRT.

105 A total of 1276 eligible participants had HRT scans of both eyes.

106 However, HRT suppresses NotchICD/CBF-1 binding to the SMA promote

107 l compared with women who did not begin HRT, HRT seemed to be much more effective in controlling hot

108 rtional hazards models were used to identify HRT variables that predicted which participants in the E

109 Thus, if HRT is to be used in women with an intact uterus, this s

110 in, CA), the Heidelberg Retina Tomograph II (HRT II; Heidelberg Engineering, GmbH, Dossenheim, German

111 th a retinal tomograph (Retina Tomograph II [HRT]; Heidelberg Engineering, Heidelberg, Germany).

112 aging with Heidelberg Retinal Tomograph III (HRT-III) (Heidelberg Engineering) CSLO within 6 months o

113 A portion of the difference in HRT and SD-OCT disc measurements is due to HRT's magnifi

114 logy of hormone receptor-positive disease in HRT users differs from that in nonusers.

115 Resistance to TCV and HRT gene expression in HRT act1 plants was inducible by SA but not by glycerol,

116 sphate dehydrogenase restored 18:1 levels in HRT ssi2 plants and reestablished a dependence on rrt.

117 n-positive hippocampal cells was observed in HRT rats that ran voluntarily on a running wheel, wherea

118 not activate this 18:1-regulated pathway in HRT plants, but instead resulted in the induction of sev

119 -light relieves this repression resulting in HRT degradation.

120 e by SA but not by glycerol, whereas that in HRT pad4 plants was inducible by glycerol but not by SA.

121 ne acetate (NETA), another progestin used in HRT, acts like an estrogen at high doses, upregulating e

122 with severe glaucoma, sensitivity increased: HRT MRA, HRT GPS, and OCT would miss 5% of eyes, and GDx

123 tance in RRT-containing plants by increasing HRT transcript levels in a PAD4-dependent manner.

124 menopausal women, ever using HRT, increasing HRT duration of use in quartiles, and increasing quartil

125 duction of oleic acid (18:1) can also induce HRT gene expression and confer resistance to TCV.

126 progresses from the upper towards the lower HRT, as reported in mice.

127 solves faster in the upper than in the lower HRT, making it appear as though infection progresses fro

128 tending from the nose down towards the lower HRT, wherein stationary cells interact with IAV which mo

129 tolic filling (enhanced lusitropy - lowering HRT), makes lymphatic contractions stronger (enhanced in

130 progestin (medroxyprogesterone acetate, MPA) HRT increases this risk.

131 re glaucoma, sensitivity increased: HRT MRA, HRT GPS, and OCT would miss 5% of eyes, and GDx would mi

132 Nevertheless, HRT is not currently used in the clinical practice.

133 g cancer for low dietary boron intake and no HRT use was 2.07 (95% CI: 1.53, 2.81).

134 n of HRT 5.3 +/- 4.5 years) and 80 in the no-HRT group (mean age 62.2 +/- 12 years).

135 th an absolute growth-rate of half of the no-HRT group (p = 0.02).

136 Univariate and multivariate analyses of HRT parameters, SD-OCT circumpapillary retinal nerve fib

137 prevents blue-light-dependent degradation of HRT, consequently these plants show resistance to TCV un

138 ulate the proteasome-mediated degradation of HRT, likely via COP1, and blue-light relieves this repre

139 an age 62.1 +/- 12.0 years; mean duration of HRT 5.3 +/- 4.5 years) and 80 in the no-HRT group (mean

140 Longer duration of HRT use (1-2 years [HR = 0.93; 95% CI = 0.87-0.99]; 3-4

141 The effect of HRT on interval breast cancer risk is not fully explaine

142 f meningioma in women without the history of HRT use was 366 in 100,000.

143 of glycerol, increased transcript levels of HRT as well as several other R genes.

144 Compared with nonuse of HRT, previous use of any (HR = 0.83; 95% CI = 0.76-0.88)

145 A number of HRT rim area progression strategies has been proposed.

146 arliest of which are present at the onset of HRT-detected ONH surface height depression.

147 nd control (nonlasered) eyes at the onset of HRT-detected surface depression (follow-up 1; [FU1]) and

148 Overexpression of HRT can compensate for the absence of PHOT2 but not CRY2

149 showed susceptibility, but overexpression of HRT coupled with high levels of endogenous SA resulted i

150 f disease severity, repeatability results of HRT-II were better than those of StratusOCT.

151 y boron may have actions similar to those of HRT; however, no previous study has reported the associa

152 We investigated whether use of HRT and duration of use was associated with risk of deve

153 he definitions of menopause and prior use of HRT as applied by the WHI investigators to the two popul

154 Since 1991, use of HRT has resulted in some 1300 additional ovarian cancers

155 elative risk for current versus never use of HRT was greater for serous than for mucinous, endometroi

156 moderate/severe periodontitis among users of HRT versus participants who did not use HRT was 0.69 amo

157 ovarian cancer in current and never users of HRT were 2.6 (2.4-2.9) and 2.2 (2.1-2.3) per 1000, respe

158 Past users of HRT were not at an increased risk of ovarian cancer (0.9

159 For current users of HRT, incidence of ovarian cancer increased with increasi

160 Among ever-users of HRT, recurrence risk was two-fold lower for estrogen rec

161 Among never-users of HRT, the expected beneficial effect of ER- or PR-positiv

162 gative tumors; whereas, among never-users of HRT, there was no statistically significant association

163 and meta-analysis of the predictive value of HRT for the end points of total mortality, CD, and fatal

164 s modestly elevated for more than 5 years of HRT use (OR = 1.41, 95% CI: 1.00, 1.99).

165 form a complex in the presence or absence of HRTs.

166 Information on HRT use was obtained at recruitment and updated where po

167 ions in Glaucoma Study (DIGS) were tested on HRT II, StratusOCT, GDx VCC, and standard automated peri

168 CA), confocal scanning laser ophthalmoscopy (HRT II; Heidelberg Engineering, Heidelberg, Germany), an

169 imaging with Scanning Laser Ophthalmoscopy (HRT), Scanning Laser Polarimetry (GDx) and Optical Coher

170 phs, confocal scanning laser ophthalmoscopy (HRT-3; Heidelberg Engineering, Heidelberg, Germany), and

171 95% confidence interval (CI): 1.04, 1.81) or HRT (OR = 1.81, 95% CI: 1.17, 2.81) and was pronounced a

172 ged 65 years or more, odds ratios for HBC or HRT use were around the null.

173 n the dark, transgenic plants overexpressing HRT showed susceptibility, but overexpression of HRT cou

174 sis of meningioma and either current or past HRT use in women.

175 ingioma in women with either current or past HRT use was 865 in 100,000, whereas the frequency of men

176 documented history of either current or past HRT use.

177 56 (11%) of whom were either current or past HRT users.

178 ,037 (5%) were documented as current or past HRT users.

179 In postacute myocardial infarction patients, HRT had pooled risk ratios of 3.53 (95% confidence inter

180 usal or who consistently take postmenopausal HRT.

181 for developing joint symptoms were previous HRT, hormone-receptor positivity, previous chemotherapy,

182 1001 of 3519 women (28.4%) without previous HRT use (odds ratio [OR] 1.72 [95% CI 1.53-1.93]).

183 reast cancer, but estrogen and progesterone (HRT) did.

184 required for the stability of the R protein HRT, and thereby resistance to Turnip Crinkle virus (TCV

185 fied as "low responders" to the Allerport(R) HRT (%HR due to anti-IgE below 20%) were excluded.

186 d 51 subjects who underwent the Allerport(R) HRT before an oral food challenge (OFC) consisting of he

187 to evaluate the utility of the Allerport(R) HRT in the diagnosis of hen's egg allergy.

188 Conclusion Allerport(R) HRT is useful for the diagnosis of hen's egg allergy, an

189 We examined whether the Allerport(R) HRT was useful as a means of diagnosing hen's egg allerg

190 normal tissues of several patients receiving HRT.

191 increased stroke severity in women receiving HRT or estrogen alone.

192 When they last reported HRT use, 287,143 women (30%) were current users and 186

193 rements of optic disc damage for OCT (RNFL), HRT (mean height contour), and GDx (RNFL) were r = 0.90

194 he inverse association remained significant (HRT OR = 0.45, 95% CI 0.30-0.66, P < 0.0001; BCP OR = 0.

195 with increased commission errors and slower HRT, adjusting for child IQ, age, sex, blood lead level,

196 or revision of the HRT operational software (HRT-3), HRT's ability to correctly classify glaucomatous

197 associated with use and duration of specific HRT formulations were calculated for total incident lung

198 e first 6 months than those who did not take HRT (60.8% v 49.2%, respectively; P = .09).

199 an older age at menopause, and never taking HRT, both in cases and controls.

200 In the tamoxifen arm, more women taking HRT at entry experienced hot flushes in the first 6 mont

201 The data suggest that women taking HRT comprising an estrogen plus MPA may have an increase

202 lts of observational studies in women taking HRT rely on self-reporting of gastro-oesophageal symptom

203 lities among 124 postmenopausal women taking HRT, treated with estrogen and progestin (E+P; n = 32),

204 T (OR = 2.59, 95% CI: 1.50, 4.46), long-term HRT use (OR = 3.93, 95% CI: 1.43, 10.84), or estrogen-pl

205 al cycle changes, while menopause, long-term HRT, and presence of milk in lactating women affected th

206 noprecipitation experiments demonstrate that HRT does not disrupt the association of NotchICD and CBF

207 We found that HRT was associated with a reduced risk of development of

208 We have previously shown that HRT-mediated resistance to TCV is dependent on SA-mediat

209 umber of prior animal studies suggested that HRT may be neuroprotective and cardioprotective.

210 The HRT GPS sensitivity was 81.5% (95% CI, 73.9%-87.6%), and

211 The HRT is a promising tool for monitoring patients with, or

212 The HRT MRA had the highest sensitivity (87.0%; 95% confiden

213 One week after the HRT session, youth completed a posttreatment assessment

214 For the HRT II parameter Moorfields regression analysis classifi

215 ds regression analysis (MRA) result from the HRT was used as a separate diagnostic classification.

216 rmany) glaucoma probability score (GPS), the HRT Moorfields regression analysis (MRA), scanning laser

217 There were 489 participants in the HRT Ancillary Study to the EGPS.

218 ed resistance to TCV via upregulation of the HRT gene.

219 elopments in the third major revision of the HRT operational software (HRT-3), HRT's ability to corre

220 rus is entrained upwards, upper parts of the HRT see more virus than lower parts.

221 milar issues were observed when reducing the HRT to 2 days, indicating that temperature<60 degrees C

222 The MM herein represents the HRT as a one-dimensional track extending from the nose d

223 With reference to the HRT TCA and OCT GPA, ONH surface depression occurred bef

224 When the HRT MRA was used as the diagnostic standard, sensitiviti

225 d of respiratory viral infections within the HRT.

226 a on the use of hormone replacement therapy (HRT) as a possible risk factor for meningioma.

227 40.6%) who used hormone replacement therapy (HRT) before trial entry developed joint symptoms compare

228 nsistently took hormone replacement therapy (HRT) between menopause and bone lead measurement (n = 14

229 jor debate when hormone replacement therapy (HRT) did not reduce coronary heart disease in postmenopa

230 Sex and hormone replacement therapy (HRT) effects on the distribution of glucose tolerance we

231 were receiving hormone replacement therapy (HRT) for alleviation of menopausal symptoms.

232 ity, and use of hormone replacement therapy (HRT) in a retrospective analysis.

233 The role of hormone replacement therapy (HRT) in lung cancer development is unclear.

234 ut the role of hormonal replacement therapy (HRT) in the development of asthma.

235 Hormone replacement therapy (HRT) increases the risk of developing breast, ovarian, a

236 Hormone replacement therapy (HRT) is widely used to manage menopausal symptoms in wom

237 Hormone replacement therapy (HRT) may reduce lung cancer risk.

238 ive history and hormone replacement therapy (HRT) or birth control pills (BCPs) influence risk for ag

239 the effects of hormone replacement therapy (HRT) use and smoking.

240 raction between hormone replacement therapy (HRT) use and tumor hormone receptor status on risk of re

241 sed duration of hormone replacement therapy (HRT) use in quartiles was associated with decreased risk

242 le consumption, hormone-replacement therapy (HRT), and estrogen exposure on the basis of menopausal s

243 tions regarding hormone replacement therapy (HRT), and provided a blood sample for serum vitamin D as

244 ceptives and in hormone replacement therapy (HRT), both on their own and in combination with EE2.

245 clinical use of hormone replacement therapy (HRT), it is critical to understand HRT effects on sensor

246 ntrol (HBC) and hormone replacement therapy (HRT), taken singly or cumulatively.

247 ring puberty is hormone replacement therapy (HRT), which delivers non-physiological levels of estroge

248 y components of hormone replacement therapy (HRT).

249 cial effects of hormone replacement therapy (HRT).

250 with the use of hormone replacement therapy (HRT).

251 current use of hormone replacement therapy (HRT; OR, 1.84; 95% CI, 1.38 to 2.44), and body mass inde

252 and diagnosis of meningioma, and therefore, HRT use may be a risk factor for meningioma.

253 rithmic associations between RNFL thickness (HRT II, StratusOCT, and GDx VCC) and neuroretinal rim ar

254 s, commission errors, and hit reaction time (HRT), with higher scores indicating increased errors or

255 At a combined hydraulic retention time (HRT) for both processes of 9 h, the effluent tCOD was re

256 of pond depth and hydraulic retention time (HRT) in response to seasonal changes.

257 teady state with a hydraulic retention time (HRT) of 1 day was reached, the process achieved complete

258 demand (COD) at a hydraulic retention time (HRT) of 11 h and reduced about 50% suspended solids.

259 grees C) at short hydraulic retention times (HRT).

260 er within 24 h (3 hydraulic retention times (HRTs)) and resume removal near 95%.

261 e modulations in diffusion parameters due to HRT and lactation should be taken into account in DTI ev

262 n HRT and SD-OCT disc measurements is due to HRT's magnification correction algorithm.

263 cells, and this effect was also sensitive to HRT inhibition.

264 severity on the Heidelberg Retina Tomograph (HRT) Glaucoma Probability Score (GPS) and the Moorfields

265 photographs and Heidelberg Retina Tomograph (HRT) images were obtained during one visit, which was wi

266 on research on Heidelberg retina tomograph (HRT) imaging of the optic nerve head in glaucoma.

267 eyes) with >/=4 Heidelberg Retina Tomograph (HRT)-II exams from the Diagnostic Innovations in Glaucom

268 be 200x200) and Heidelberg Retina Tomograph (HRT).

269 etry (SAP) and Heidelberg Retinal Tomograph (HRT II) were both more sensitive than GAT (41, 95% CrI 1

270 maged by CSLO (Heidelberg Retinal Tomograph [HRT]; Heidelberg Engineering, GmbH, Dossenheim, Germany)

271 ophthalmoscopy (Heidelberg Retina Tomograph; HRT).

272 g the MMDT and Heidelberg Retina Tomography (HRT; Heidelberg Engineering, Heidelberg, Germany) scanni

273 gorithms: the Heidelberg Retinal Tomography (HRT; Heidelberg Engineering, Heidelberg, Germany) glauco

274 y parameters (Heidelberg Retinal Tomography [HRT]; Heidelberg Engineering, Heidelberg, Germany).

275 Within the human respiratory tract (HRT), virus diffuses through the periciliary fluid (PCF)

276 The traditional HRT low responders (n=27) were separated into two groups

277 nse trainer (LRT) and high-response trainer (HRT) adult male rats to various forms of physical exerci

278 a single session of habit reversal training (HRT) augmented by either 50 mg of DCS or placebo.

279 enous levels of Hairy Related Transcription (HRT) factor 2 (HRT2) peaked concurrently with inhibitory

280 Heart rate turbulence (HRT) has been proposed as a candidate marker of altered

281 ght induces degradation of CRY2, and in turn HRT, resulting in susceptibility.

282 therapy (HRT), it is critical to understand HRT effects on sensory systems.

283 s of HRT versus participants who did not use HRT was 0.69 among participants who were vitamin D suffi

284 women who consumed low boron and did not use HRT were at substantial increased odds.

285 Women who use HRT are at an increased risk of both incident and fatal

286 Because millions of women use HRT, it is important to consider how the WHI and other r

287 re years, compared with women who never used HRT (adjusted odds ratio = 3.4, 95% confidence interval

288 teers and postmenopausal volunteers who used HRT (P = .31-0.93).

289 omen with high dietary boron intake who used HRT, the odds ratio for lung cancer for low dietary boro

290 Among postmenopausal women, ever using HRT, increasing HRT duration of use in quartiles, and in

291 t-retest variability of ONH topography using HRT-II and StratusOCT increased with increasing disease

292 ractions were examined, to determine whether HRT or BCP modifies the effect of established genetic ri

293 All pair-wise HRT-genotype and BCP-genotype interactions were examined

294 Risks associated with HRT varied significantly according to tumour histology (

295 ct and was in better agreement than CAP with HRT-determined rim area.

296 hout HRT use as compared with the group with HRT use (P < .01) and premenopausal volunteers (P < .01)

297 D) and whether genetic factors interact with HRT to modulate AMD risk.

298 vidence suggesting that ARMS2 interacts with HRT to modulate AMD risk and are consistent with previou

299 ce to Topographic Change Analysis (TCA) with HRT and Guided Progression Analysis (GPA) with Cirrus HD

300 , and optic nerve head (ONH) topography with HRT-II (retinal tomograph; Heidelberg Engineering GmbH,

301 significantly lower (a) in the group without HRT use as compared with the group with HRT use (P < .01